Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! By
Rna Therapies in Cancer Publisher



F Khatami FATEMEH ; S Zahedian SETAREH ; L Zareian LEILA ; R Mashhadi RAHIL ; M Hasanzad MANDANA ; Z Ahadi ZEINAB ; Smk Aghamir Seyed Mohamamd KAZEM
Authors

Source: Published:2024


Abstract

RNA-based therapies have emerged as promising cancer treatment strategies, with precision targeting and potentially fewer off-target effects than traditional approaches. These treatments take advantage of the diverse nature of RNA molecules to control gene expression, inhibit oncogenic pathways, and enhance immune responses against malignancies. By specifically targeting cancer cells, RNA-based therapies have the potential to minimize damage to healthy tissue and reduce the side effects commonly associated with chemotherapy and radiation. The development of these therapies represents a significant advancement in the field of oncology, offering new hope for patients with difficult-to-treat cancers. As research continues to uncover the full potential of RNA-based treatments, the future of cancer therapy looks increasingly promising. © 2025 Elsevier B.V., All rights reserved.
Related Docs
View other Related Docs
1. The Clinical Impact of Mrna Therapeutics in the Treatment of Cancers, Infections, Genetic Disorders, and Autoimmune Diseases, Heliyon (2024)
2. Immune Checkpoints and Ncrnas: Pioneering Immunotherapy Approaches for Hematological Malignancies, Cancer Cell International (2024)
3. Mrna Cancer Vaccines From Bench to Bedside: A New Era in Cancer Immunotherapy, Biomarker Research (2024)
Experts (# of related papers)
View all Related Experts
Mohammad Hossein Modarressi (2)
Fereydon Memari (2)
Other Related Docs
4. Roles of Non-Coding Rnas in Cell Death Pathways Involved in the Treatment of Resistance and Recurrence of Cancer, Pathology Research and Practice (2023)
5. Lncrna-Mediated Regulation of Cisplatin Response in Breast Cancer, Pathology, research and practice (2024)
6. Small Interfering Rnas (Sirnas) in Cancer Therapy: A Nano-Based Approach, International journal of nanomedicine (2019)
7. Competing Endogenous Rnas Regulatory Crosstalk Networks: The Messages From the Rna World to Signaling Pathways Directing Cancer Stem Cell Development, Heliyon (2024)
8. Lung Cancer Vaccine Strategies: Exploring the Spectrum From Traditional to Rna-Based Platforms, Frontiers in Bioengineering and Biotechnology (2025)
9. Non-Coding Rnas in Cancer Immunotherapy: A Solution to Overcome Immune Resistance?, Progress in Molecular Biology and Translational Science (2024)
10. Types of Rna Therapeutics, Progress in Molecular Biology and Translational Science (2024)
11. Critical Role of the Long Non-Coding Rnas (Lncrnas) in Radiotherapy (Rt)-Resistance of Gastrointestinal (Gi) Cancer: Is There a Way to Defeat This Resistance?, Pathology Research and Practice (2024)
12. Long Non-Coding Rnas: Potential Players in Cardiotoxicity Induced by Chemotherapy Drugs, Cardiovascular Toxicology (2022)
13. The Expression of the Lncrnas Usp30-As1, Elfn1-As1, Gas8-As1, and Snhg11 in Breast Cancer Samples From Iranian Patients From 2014 to 2019: A Cross-Sectional Study, BMC Research Notes (2025)
14. Lncrnas and Mirnas: New Targets for Resveratrol in Ovarian Cancer Research, Current Medicinal Chemistry (2023)
15. Antibody-Drug Therapeutic Conjugates: Potential of Antibody-Sirnas in Cancer Therapy, Journal of Cellular Physiology (2019)
16. Microrna a New Gate in Cancer and Human Disease: A Review, Journal of Biological Sciences (2017)
17. Stimuli-Responsive Mesoporous Silica Nps As Non-Viral Dual Sirna/Chemotherapy Carriers for Triple Negative Breast Cancer, Molecular Therapy Nucleic Acids (2017)
18. Recent Progress in the Immunotherapy of Hepatocellular Carcinoma: Non-Coding Rna-Based Immunotherapy May Improve the Outcome, Biomedicine and Pharmacotherapy (2023)
19. Deciphering the Oncogenic Landscape: Unveiling the Molecular Machinery and Clinical Significance of Lncrna Tmpo-As1 in Human Cancers, Pathology Research and Practice (2024)
20. Inhibition of Mir-155 in Mcf-7 Breast Cancer Cell Line by Gold Nanoparticles Functionalized With Antagomir and As1411 Aptamer, Journal of Cellular Physiology (2020)